POSKX
Price
$39.74
Change
-$1.26 (-3.07%)
Updated
Jun 5 closing price
Net Assets
4.8B
VTSAX
Price
$176.85
Change
-$4.87 (-2.68%)
Updated
Jun 5 closing price
Net Assets
2.31T
Interact to see
Advertisement

POSKX vs VTSAX

Header iconPOSKX vs VTSAX Comparison
Open Charts POSKX vs VTSAXBanner chart's image
POSKX vs VTSAX Comparison Chart in %
View a ticker or compare two or three
VS
POSKX vs. VTSAX commentary
Jun 06, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is POSKX is a Buy and VTSAX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VTSAX has more cash in the bank: 2.31T vs. POSKX (4.8B). VTSAX pays higher dividends than POSKX: VTSAX (1.00) vs POSKX (0.77). POSKX was incepted earlier than VTSAX: POSKX (22 years) vs VTSAX (26 years). POSKX (0.67) is less costly to investors than VTSAX (0.04). POSKX is a more actively managed with annual turnover of: 9.00 vs. VTSAX (3.00). POSKX has a lower initial minimum investment than VTSAX: POSKX (2000) vs VTSAX (3000). VTSAX annual gain was more profitable for investors over the last year : 27.94 vs. POSKX (20.19). VTSAX return over 5 years is better than : 70.95 vs. POSKX (1.49).
POSKXVTSAXPOSKX / VTSAX
Total Expense Ratio0.670.041,675%
Annual Report Gross Expense Ratio0.670.041,675%
Fund Existence22 years26 years-
Gain YTD23.60611.370208%
Front LoadN/AN/A-
Min. Initial Investment2000300067%
Min. Initial Investment IRAN/AN/A-
Net Assets4.8B2.31T0%
Annual Yield % from dividends0.771.0077%
Returns for 1 year20.1927.9472%
Returns for 3 years22.9275.6730%
Returns for 5 years1.4970.952%
Returns for 10 years85.48257.9933%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BCDA1.070.15
+16.43%
BioCardia Inc.
DTE145.773.04
+2.13%
DTE Energy Company
SLGN36.630.35
+0.96%
Silgan Holdings
PLX1.99-0.02
-1.00%
Protalix BioTherapeutics
REPL9.47-0.40
-4.05%
Replimune Group